Immunovant (IMVT) Net Cash Flow (2019 - 2026)

Immunovant's Net Cash Flow history runs 8 years deep, the most recent figure standing at -$91.4 million for Q1 2026.

• Quarterly Net Cash Flow fell 126.91% year-over-year to -$91.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.4 million (up 142.02% YoY) and the FY2026 annual result came in at $188.4 million, up 142.02% from the prior year.
• Net Cash Flow was -$91.4 million for Q1 2026 at Immunovant, down from $472.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $472.3 million in Q4 2025 and bottomed at -$114.5 million in Q2 2025.
• A 5-year average of $22.0 million and a median of -$58.3 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 211.43% — and 2023, when it soared 1650.83%.
• Immunovant's Net Cash Flow stood at $24.1 million in 2022, then surged by 1650.83% to $422.6 million in 2023, then slumped by 123.21% to -$98.1 million in 2024, then soared by 581.39% to $472.3 million in 2025, then plunged by 119.36% to -$91.4 million in 2026.
• Business Quant data shows IMVT's Net Cash Flow at -$91.4 million in Q1 2026, $472.3 million in Q4 2025, and -$77.9 million in Q3 2025.